Search results
Showing 1951 to 2000 of 2990 results for all
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)
Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.
View recommendations for HTG110Show all sections
Sections for HTG110
YAG laser vitreolysis for symptomatic vitreous floaters (HTG644)
Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.
View recommendations for HTG644Show all sections
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (HTG653)
Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.
View recommendations for HTG653Show all sections
Extracorporeal shockwave therapy for refractory plantar fasciitis (HTG200)
Evidence-based recommendations on extracorporeal shockwave therapy for refractory plantar fasciitis. This involves using a machine to deliver sound waves to the painful area, with the aim to stimulate healing of the fascia.
View recommendations for HTG200Show all sections
Sections for HTG200
Corneal inlay implantation for correction of presbyopia (HTG311)
Evidence-based recommendations on corneal inlay implantation for correction of Presbyopia. This involves placing a disc inside a flap or pocket made in the cornea to improve near vision.
View recommendations for HTG311Show all sections
Sections for HTG311
Vagus nerve stimulation for refractory epilepsy in children (HTG25)
Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.
View recommendations for HTG25Show all sections
Sections for HTG25
Evidence-based recommendations on autologous blood injection for plantar fasciitis. This involves supplying the connective tissue with growth factors that promote the healing process.
View recommendations for HTG298Show all sections
Sections for HTG298
Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids (HTG277)
Evidence-based recommendations on magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. This involves using magnetic resonance imaging (MRI) to locate the fibroids and direct high-intensity ultrasound energy to destroy fibroid tissue.
View recommendations for HTG277Show all sections
Sections for HTG277
Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.
View recommendations for HTG265Show all sections
Sections for HTG265
Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction in adults. This involves using a device to improve blood flow to the penis.
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)
Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.
View recommendations for HTG122Show all sections
Sections for HTG122
Evidence-based recommendations on laparoscopic cystectomy. This involves removing the bladder using small cuts in the abdomen (keyhole surgery).
View recommendations for HTG181Show all sections
Sections for HTG181
Selective dorsal rhizotomy for spasticity in cerebral palsy (HTG245)
Evidence-based recommendations on selective dorsal rhizotomy for spasticity in cerebral palsy. This involves cutting nerves in the lower spine that are responsible for muscle rigidity.
View recommendations for HTG245Show all sections
Sections for HTG245
Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina (HTG464)
Evidence-based recommendations on laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. This involves inserting mesh to hold the uterus or the top of the vagina in place.
View recommendations for HTG464Show all sections
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Percutaneous tibial nerve stimulation for faecal incontinence (HTG263)
Evidence-based recommendations on percutaneous tibial nerve stimulation (PTNS) for faecal incontinence. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current through the needle to the nerves that control bowel function.
View recommendations for HTG263Show all sections
Sections for HTG263
Evidence-based recommendations on single-port laparoscopic nephrectomy. This involves removing the kidney using several small incisions (laparoscopy).
View recommendations for HTG278Show all sections
Sections for HTG278
Arthroscopic femoro–acetabular surgery for hip impingement syndrome (HTG273)
Evidence-based recommendations on arthroscopic femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.
View recommendations for HTG273Show all sections
Sections for HTG273
Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.
View recommendations for HTG168Show all sections
Sections for HTG168
Endoscopic submucosal dissection of gastric lesions (HTG233)
Evidence-based recommendations on endoscopic submucosal dissection (ESD) of gastric lesions. This involves inserting a thin telescope through the mouth into the stomach to view the area and removing the lesion with special equipment.
View recommendations for HTG233Show all sections
Sections for HTG233
Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (HTG458)
Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to destroy sweat glands in the armpit.
Selective peripheral denervation for cervical dystonia (HTG51)
Evidence-based recommendations on selective peripheral denervation for cervical dystonia. This involves cutting the nerves to the muscles of the neck through a large skin incision.
View recommendations for HTG51Show all sections
Sections for HTG51
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)
NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Balloon dilation for chronic eustachian tube dysfunction (HTG534)
Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.
View recommendations for HTG534Show all sections
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)
Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)
Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.